Safety, Pharmacokinetics, and Pharmacodynamics of Supratherapeutic Multiple Doses of Iptacopan in Healthy Participants: A Phase 1 Randomized, Double-Blinded, Placebo-Controlled Study

Iptacopan is an orally administered proximal complement inhibitor targeting factor B to selectively inhibit the alternative pathway of the complement system, while sparing activity of the classical pathway. Previous studies have shown that iptacopan is rapidly absorbed, reaching maximum concentration in approximately 1–2 h, and that dose–exposure proportionality is achieved after multiple doses of 100 mg and 200 mg twice daily (BID). The approved clinical dose is 200 mg BID. This study evaluated the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of multiple supratherapeutic doses of iptacopan (400 and 800 mg BID) in healthy adult participants. The trial was a randomized, placebo-controlled, double-blinded phase 1 multiple-ascending-dose study conducted in two sequential cohorts. A total of 26 participants were randomized 2:1 to BID iptacopan 400 mg or 800 mg for 14 days or matching placebo; 24 participants completed the study. Treatment-emergent adverse events (TEAEs) were mild to moderate, and there were no serious AEs, deaths, or discontinuations due to AEs. The most frequent TEAE was headache, occurring in five (20.8%) participants. Plasma measures of iptacopan exposure appeared to increase in a dose-proportional manner, and biomarker analyses showed that there was rapid, near-complete, and persistent inhibition of alternative pathway activity for both doses, measured by the Wieslab assay. These findings show that iptacopan supratherapeutic doses of 400 mg and 800 mg BID are well tolerated in healthy participants and describe the PK and PD properties of iptacopan and inhibition of the alternative complement pathway.

Authors

Institutions

Publication Details

Journal
European Journal of Drug Metabolism and Pharmacokinetics
Published
2026-11-14
DOI
https://doi.org/10.1007/s13318-026-01043-9
Primary Topic
Complement system in diseases
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Safety, Pharmacokinetics, and Pharmacodynamics of Supratherapeutic Multiple Doses of Iptacopan in Healthy Participants: A Phase 1 Randomized, Double-Blinded, Placebo-Controlled Study

Bharti Shah, Suleyman Eralp Bellibas, Melissa Hackling, Kenneth M. Kulmatycki et al.
European Journal of Drug Metabolism and Pharmacokinetics
Complement system in diseases
article

Safety, Pharmacokinetics, and Pharmacodynamics of Supratherapeutic Multiple Doses of Iptacopan in Healthy Participants: A Phase 1 Randomized, Double-Blinded, Placebo-Controlled Study

Bharti Shah, Suleyman Eralp Bellibas, Melissa Hackling, Kenneth M. Kulmatycki, Robert Schmouder, Mohammed Hisham Mecheri, Marie-Anne Valentin
article en

Abstract

Iptacopan is an orally administered proximal complement inhibitor targeting factor B to selectively inhibit the alternative pathway of the complement system, while sparing activity of the classical pathway. Previous studies have shown that iptacopan is rapidly absorbed, reaching maximum concentration in approximately 1–2 h, and that dose–exposure proportionality is achieved after multiple doses of 100 mg and 200 mg twice daily (BID). The approved clinical dose is 200 mg BID. This study evaluated the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of multiple supratherapeutic doses of iptacopan (400 and 800 mg BID) in healthy adult participants. The trial was a randomized, placebo-controlled, double-blinded phase 1 multiple-ascending-dose study conducted in two sequential cohorts. A total of 26 participants were randomized 2:1 to BID iptacopan 400 mg or 800 mg for 14 days or matching placebo; 24 participants completed the study. Treatment-emergent adverse events (TEAEs) were mild to moderate, and there were no serious AEs, deaths, or discontinuations due to AEs. The most frequent TEAE was headache, occurring in five (20.8%) participants. Plasma measures of iptacopan exposure appeared to increase in a dose-proportional manner, and biomarker analyses showed that there was rapid, near-complete, and persistent inhibition of alternative pathway activity for both doses, measured by the Wieslab assay. These findings show that iptacopan supratherapeutic doses of 400 mg and 800 mg BID are well tolerated in healthy participants and describe the PK and PD properties of iptacopan and inhibition of the alternative complement pathway.

European Journal of Drug Metabolism and Pharmacokinetics
Novartis (Switzerland) (CH), Novartis (India) (IN), Novartis Institutes for BioMedical Research (CH)
Complement system in diseases
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon